9L47 image
Entry Detail
PDB ID:
9L47
Keywords:
Title:
Crystal structure of HLA-C*12:03-MY9
Biological Source:
Source Organism:
Host Organism:
PDB Version:
Deposition Date:
2024-12-20
Release Date:
2025-03-19
Method Details:
Experimental Method:
Resolution:
2.80 Å
R-Value Free:
0.26
R-Value Work:
0.20
R-Value Observed:
0.21
Space Group:
P 1 21 1
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:MHC class I antigen
Chain IDs:A, D
Chain Length:273
Number of Molecules:2
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Description:Beta-2-microglobulin
Chain IDs:B, E
Chain Length:99
Number of Molecules:2
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Description:MY9
Chain IDs:C, F
Chain Length:9
Number of Molecules:2
Biological Source:Homo sapiens
Ligand Molecules
Primary Citation
Biochemical and structural insights into position 97 micropolymorphisms in human leukocyte antigen (HLA)-C*12 allotypes and their differential disease associations.
Int.J.Biol.Macromol. 306 141681 141681 (2025)
PMID: 40044006 DOI: 10.1016/j.ijbiomac.2025.141681

Abstact

Micropolymorphisms drastically shape the antigen presentation characteristics of human leukocyte antigen class I (HLA-I) molecules, with profound implications for immune responses and disease susceptibility. HLA-C*12:02 and HLA-C*12:03 are closely related HLA-I allotypes that differ by a single amino acid substitution (R97W) but exhibit distinct associations with disease. HLA-C*12:02 has been shown to provide protective effects against HIV infection, playing a crucial role in controlling viral replication and slowing disease progression, whereas HLA-C*12:03 is associated with increased susceptibility to psoriasis. We determined the X-ray crystal structures of the two allotypes presenting MARELHPEY (MY9) and RAFPGLRYV (RV9). Peptide residues that function as anchors, as well as those accessible for T-cell antigen receptor (TCR) contact, were identified. Our results, combined with those of biochemical studies, demonstrated that the R97W variation alters the peptide-binding groove (PBG) volume and charge, leading to conformational and stability changes in pHLA-C*12 complexes and ultimately affecting peptide-binding preferences for the two HLA-C*12 allotypes. This research not only advances our understanding of the impact of HLA-I micropolymorphisms but also offers clues for the use of structure-guided therapeutics to interfere with peptide binding.

Legend

Protein

Chemical

Disease

Primary Citation of related structures